申万菱信中证申万医药生物指数(LOF)C(015176)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-28,388,174.07 |
-47,282,035.18 |
-29,254,096.02 |
-19,680,001.71 |
| 利息合计 |
116,178.67 |
58,911.46 |
140,620.83 |
72,389.62 |
| 其中：存款利息收入 |
116,178.67 |
58,911.46 |
140,620.83 |
72,389.62 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-12,446,376.86 |
-11,837,915.24 |
-10,569,346.53 |
-1,776,540.21 |
| 其中：股票投资收益 |
-16,658,365.28 |
-14,285,005.21 |
-14,052,407.09 |
-4,304,157.60 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
4,211,988.42 |
2,447,089.97 |
3,483,060.56 |
2,527,617.39 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-16,098,130.43 |
-35,511,523.04 |
-18,855,461.11 |
-17,996,079.20 |
| 其他收入 |
40,154.55 |
8,491.64 |
30,090.79 |
20,228.08 |
| 费用 |
3,127,340.16 |
1,591,581.48 |
3,785,989.89 |
1,951,592.25 |
| 管理人报酬 |
2,346,196.71 |
1,195,235.04 |
2,839,118.94 |
1,462,192.34 |
| 基金托管费 |
469,239.28 |
239,047.03 |
604,825.73 |
321,682.25 |
| 销售服务费 |
88,930.06 |
45,659.63 |
108,520.04 |
50,395.02 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
222,974.11 |
111,639.78 |
233,525.18 |
117,322.64 |
| 利润总额 |
-31,515,514.23 |
-48,873,616.66 |
-33,040,085.91 |
-21,631,593.96 |
微信公众号
证券之星APP
基本资料
